Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 29 Sept 2020 |
| Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen | 22 Sept 2020 |
| Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 | 21 Sept 2020 |
| Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference | 9 Sept 2020 |
| Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020 | 27 Aug 2020 |